Pharmacokinetics of Gadodiamide Injection in Patients with Moderately Impaired Renal Function

Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function

“…This effect closely resembles that described previously for other gadolinium chelates. 4 Based on serum creatinine measurements, OptiMARK had no adverse effect on kidney function. Despite the increased exposure time in subjects with renal impairment, OptiMARK appeared to be safe and was well tolerated by all participants in this trial.…”

Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents

“…of the Omniscan-treated animals correspond to about 0.081% of the total dose of Omniscan administered. This small fraction of Gd may explain why earlier pharmacokinetic studies failed to detect any Gd retention [25]. The difference in retained Gd between Omniscan and OptiMARK treatment may be related to the difference in the amount of excess ligand in the formulation of these two GBCAs [26].…”

Clinical evaluation of gadodiamide injection in paediatric MR imaging

“…Gadodiamide injection is, like other extracellular MRI contrast media, freely distributed to the extracellular space and is excreted through the kidneys at a rate dependant on the glomerular filtration rate (GFR) [9,10]. In children about 6 months of age and older, both GFR and the relative volume of the extracellular space are comparable to those in adults and the elimination of injected gadodiamide is assumed to be as in adults.…”